

Tirzepatide (Mounjaro) implementation update 10 July 25

Thank you for your continued patience whilst we have been working on the NHS England implementation requirements for Tirzepatide with Practices. Most components of delivery have been put in place, here is an update:

Primary Care Delivery Model and offer to Practices – Practices have been sent an Expressions of Interest (EOI) and a LES service specification for the delivery of Tirzepatide in primary care for weight management from the primary care contracts team. Thank you for your quick turnaround of responses, we have nearly 80% of Practices who have had expressed an interest in the offer of the LES. If you haven't made a return, we would be grateful if this could be done as soon as possible so we can mitigate any potential gaps in delivery.

Tirzepatide prescribing guidance – this prescribing guidance has been approved by the BNSSG Weight Management Working Group for Practices signed up to the LES. We hope that Practices find it helpful.



Tirzepatide BNSSG
Prescribing Guidance

NHSE Wraparound Care (WAC) provider – the referral form for Behavioural Support for Obesity Prescribing (BSOP) through Living Well Taking Control is available in EMIS and can only be completed for **patients who meet the NHSE year 1 cohort 1 criteria** who decide to take up the offer of Tirzepatide treatment. A reminder that it is a 9-month programme and patients will be offered a choice of three delivery models:

1. Face to face group sessions
2. Remote digital groups sessions
3. Fully digital delivery

Primary Care Eligible Cohort

A reminder that the primary care eligibility criteria for the NHSE cohort 1 in Year 1 is as follows:

- BMI ≥ 40 and
- ≥ 4 'qualifying' comorbidities – hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus

Use a lower BMI threshold (usually reduced by 2.5 kg/m²) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

We have sent searches to support Practices identify patients within the primary care cohort 1 for assessment of eligibility. These are also embedded in below Word document below.



Tirzepatide Cohort
1 Patient Case Findii

Support Practices with patient flow – we have developed some wording for text messaging that Practices may wish to adopt/adapt to send to patients that may be eligible for Tirzepatide treatment. We have considered the words used to provide a compassionate and supportive approach.

We have reviewed the records we have for you and note that you may be eligible for treatment with Tirzepatide (Mounjaro) for weight management to help improve health and wellbeing with support. If you are happy to speak with us about this, please get in contact to make an appointment and find out more.

Training for Primary Care – a live Teams webinar for Practices was held on Wednesday 11 June 25 and was recorded. Practice staff who registered for the event and attended the session should have received a link to the recorded webinar and a copy of the slide deck.

If you would like a link to the recorded webinar and copy of the slide deck, please contact bnssg.medicines-optimisation@nhs.net.

We will let Practices know where to find this webinar and other resources when a web page has been published.

GP IT templates

Two templates are now available, one in Ardens the other from NHSE.

The BNSSG Weight Management Group recommends that the Ardens '[NHS Obesity Medication Pathway](#)' template is used as a clinical tool to support assessment of eligibility, medication initiation, medication review and record of wraparound pathway. This template also supports the key metrics that NHSE require to be completed to support funding for the ICB.

NHSE have also provided a GP IT template. This has not been developed as a clinical tool but to capture the key NHSE metrics. The NHSE GP IT Template is available via [Obesity Medication Pathway](#). This website requires Practices to complete a web form to gain access.

Note: Ardens does not capture Severe Mental Health Diagnosis, Learning Disability or Eating Disorder whereas the NHS GP IT template does. We would recommend these are recorded where appropriate and considered in the context of whether the individual needs additional support to understand or meet the demands of tirzepatide and wraparound care and/or monitoring requirements, including the self-administration and the required storage.

Patient Information and communication

- We have recently added local information for the public on the BNSSG ICB website to provide information for patients and support to Practices [Tirzepatide \(Mounjaro®\) - BNSSG Healthier Together](#)
- NHSE have national FAQs for patients and this can be found on the Joint Formulary Remedy website - [Tirzepatide FAQs for patients](#)
- **Further information** can be found on Remedy at [Weight Management - Tirzepatide \(Mounjaro\) \(Remedy BNSSG ICB\)](#)

Year 2 and beyond

The work that has been undertaken to date has been to support the implementation of the NHSE cohort 1 for year 1 and the LES has been developed to support this. NHSE have provided information on Year 2 and 3 cohorts and locally we have already started to work on year 2, bearing in mind that there will be patients in their first year of treatment mixed with patients in their second. We have modelled patient numbers, and the weight management group will agree the model for year 2 and beyond over the next few months. We recognise that this is a new pathway in primary care and that it will be an iterative process to continually refine the model of care over the coming years, considering the capacity within primary care. Noting that the funding envelope provided to us by NHSE for year 2 is the same for year 1 we will have scope to review the LES based on Practice feedback and experiences in addition to patient experiences and outcomes.

We will update you with further information as soon as it becomes available to share with you.
bnssg.medicines-optimisation@nhs.net